Published in BMC Cancer on August 11, 2005
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07
The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform (2007) 0.98
Taxane pathway. Pharmacogenet Genomics (2009) 0.94
Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Mol Cancer Ther (2011) 0.84
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
Cancer burden in the year 2000. The global picture. Eur J Cancer (2001) 10.47
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 5.51
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
Characterization of the human p53 gene. Mol Cell Biol (1986) 4.33
Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol (1998) 3.03
Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst (2001) 2.88
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
The taxanes: an update. Lancet (2000) 2.55
Bcl2 is the guardian of microtubule integrity. Cancer Res (1997) 2.51
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res (1996) 2.37
Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer (2000) 2.29
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Cellular and molecular determinants of cisplatin resistance. Eur J Cancer (1998) 1.82
BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol (1998) 1.80
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol (1999) 1.58
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci U S A (1994) 1.56
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res (1997) 1.47
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer (1998) 1.46
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer (1999) 1.45
A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem (1999) 1.43
Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer (1995) 1.31
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
Chemotherapy of advanced ovarian cancer. Semin Oncol (1998) 1.24
Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol (2004) 1.08
Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol (1998) 1.05
Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol (1997) 1.03
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther (2002) 0.97
Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis (1996) 0.97
Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer (2002) 0.96
Genetic alterations distinguish different types of ovarian tumors. Int J Cancer (1995) 0.95
Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol (1999) 0.94
Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer (1998) 0.91
Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol (1999) 0.91
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann Oncol (1998) 0.89
Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer (2003) 0.88
Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett (2003) 0.87
beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res (2003) 0.86
[What's new about microsatellite instability significance in human carcinogenesis?]. Bull Cancer (1997) 0.79
An expressed beta-tubulin gene, TUBB, is located on the short arm of human chromosome 6 and two related sequences are dispersed on chromosomes 8 and 13. Exp Cell Res (1986) 0.78
Evolution of MRSA during hospital transmission and intercontinental spread. Science (2010) 13.34
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia (2006) 2.48
SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res (2005) 2.20
Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol (2006) 2.19
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat (2006) 2.04
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer (2006) 1.67
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol (2004) 1.62
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood (2013) 1.59
High genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter study. PLoS One (2012) 1.53
The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat (2008) 1.51
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol (2006) 1.48
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Carcinoma of the thyroid with ewing family tumor elements and favorable prognosis: report of a second case. Int J Surg Pathol (2013) 1.46
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics (2011) 1.20
MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18
E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer (2004) 1.17
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer (2011) 1.17
Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosomes Cancer (2010) 1.14
8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. Int J Cancer (2003) 1.14
Genome signatures of colon carcinoma cell lines. Cancer Genet Cytogenet (2004) 1.13
DNA repair genes are selectively mutated in diffuse large B cell lymphomas. J Exp Med (2013) 1.12
8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res (2006) 1.11
Heterogeneous genetic profiles in soft tissue myoepitheliomas. Mod Pathol (2008) 1.10
Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res (2006) 1.09
Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer (2008) 1.08
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer (2007) 1.06
EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumour Biol (2012) 1.05
Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer (2006) 1.04
Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res (2003) 1.03
Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer (2004) 1.03
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem (2011) 1.02
DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat (2006) 1.02
A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. Mol Cancer (2009) 1.01
Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer (2010) 1.01
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer (2006) 1.00
FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clin Endocrinol (Oxf) (2012) 1.00
Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics (2010) 0.99
Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat (2007) 0.99
Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol (2003) 0.96
Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. Genes Chromosomes Cancer (2003) 0.95
Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. Cancer Genet (2011) 0.95
Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer (2011) 0.95
Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer (2010) 0.94
MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer (2010) 0.94
Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS One (2011) 0.94
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol (2005) 0.93
Cytogenetic characterization of tumors of the vulva and vagina. Genes Chromosomes Cancer (2003) 0.93
G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun (2005) 0.92
Intraepidermal epidermotropic metastatic melanoma: a clinical and histopathological mimicker of melanoma in situ occurring in multiplicity. J Cutan Pathol (2011) 0.92
Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene. Pediatr Blood Cancer (2011) 0.91
Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. Mol Cancer (2004) 0.91
Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J (2002) 0.91
Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandom involvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet (2003) 0.91
Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. J Exp Med (2012) 0.91
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat (2010) 0.91
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med (2014) 0.90
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol (2004) 0.89
Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. Apoptosis (2010) 0.89
CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Mod Pathol (2009) 0.89
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A (2013) 0.89
Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. Cell Oncol (2008) 0.89
Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. Genes Chromosomes Cancer (2004) 0.89
Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. BMC Genomics (2014) 0.89
Genome profiling of breast cancer cells selected against in vitro shows copy number changes. Genes Chromosomes Cancer (2002) 0.88
Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. Genes Chromosomes Cancer (2010) 0.88
TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun (2005) 0.88
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer (2006) 0.88
Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol (2010) 0.88
Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. Eur J Endocrinol (2013) 0.88
Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Res Treat (2013) 0.87
TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. Fam Cancer (2009) 0.86
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet (2009) 0.86